In a considerable part of breast carcinomas the amount of cell surface Her2/neu receptors has been increased such that it becomes the main factor defining the behaviour of the tumor. At the same time, in such amount, this receptor is easily detectable by simple, routine pathological methods. If we are aware of the exact biological characteristics of a given tumor, targeted therapy may be used since an antibody against the Her2 receptor is already available. This drug, called trastuzumab (Herceptin), has been used in advanced breast carcinoma as adjuvant or primary treatment. In clinical trials its advantage in early stage breast carcinomas has been investigated so far.
|Number of pages||6|
|Publication status||Published - Dec 1 2005|
ASJC Scopus subject areas